Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Most clinical evidence linking GLP-1 use to IBS improvement comes from observational data rather than randomized controlled trials, meaning causality cannot be definitively established
Available online at: (Accessed January 1, 2022)
Accessed 3/31/2016 Mazza A, Fruci B, Garinis GA, et al
Stop use with severe nausea, dizziness, or unusual skin changes
Bigger trials, run over longer stretches of time, are the obvious next step
Slow dose escalation mitigates these effects substantially, and discontinuation due to gastrointestinal intolerance ranges from 3% to 16% across agents, being highest for GLP-1/glucagon dual agonists (e.g., survodutide)
US$ 28.87
US$ 22.06
US$ 24.13
US$ 27.12
US$ 27.74
US$ 22.45
US$ 25.41
US$ 28.04
US$ 22.63
US$ 20.15
US$ 22.62
US$ 27.00
US$ 24.09
